Fox Run Management L.L.C. Sells 11,123 Shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE)

Fox Run Management L.L.C. cut its stake in Xenon Pharmaceuticals Inc. (NASDAQ:XENE) by 56.3% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 8,621 shares of the biopharmaceutical company’s stock after selling 11,123 shares during the period. Fox Run Management L.L.C.’s holdings in Xenon Pharmaceuticals were worth $338,000 at the end of the most recent quarter.

Other institutional investors have also recently modified their holdings of the company. KLP Kapitalforvaltning AS acquired a new position in Xenon Pharmaceuticals in the fourth quarter valued at about $502,000. Magnetar Financial LLC bought a new position in Xenon Pharmaceuticals in the 4th quarter valued at about $210,000. Teacher Retirement System of Texas raised its position in shares of Xenon Pharmaceuticals by 18.6% in the 4th quarter. Teacher Retirement System of Texas now owns 19,083 shares of the biopharmaceutical company’s stock valued at $748,000 after buying an additional 2,994 shares in the last quarter. Swiss National Bank lifted its holdings in shares of Xenon Pharmaceuticals by 1.0% during the 4th quarter. Swiss National Bank now owns 126,600 shares of the biopharmaceutical company’s stock worth $4,963,000 after acquiring an additional 1,300 shares during the period. Finally, Zurcher Kantonalbank Zurich Cantonalbank boosted its position in shares of Xenon Pharmaceuticals by 17.5% during the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 19,274 shares of the biopharmaceutical company’s stock worth $756,000 after acquiring an additional 2,866 shares in the last quarter. 95.45% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

XENE has been the subject of several research analyst reports. Royal Bank of Canada restated an “outperform” rating on shares of Xenon Pharmaceuticals in a research report on Friday, February 28th. William Blair reiterated an “outperform” rating on shares of Xenon Pharmaceuticals in a research note on Friday, February 28th. Deutsche Bank Aktiengesellschaft started coverage on Xenon Pharmaceuticals in a research report on Tuesday, February 11th. They set a “buy” rating and a $67.00 price objective for the company. Finally, HC Wainwright reiterated a “buy” rating and issued a $53.00 target price on shares of Xenon Pharmaceuticals in a research report on Monday, February 24th. Nine research analysts have rated the stock with a buy rating, According to data from MarketBeat, the company currently has a consensus rating of “Buy” and an average target price of $57.38.

Xenon Pharmaceuticals Trading Down 0.3 %

Xenon Pharmaceuticals stock opened at $34.78 on Thursday. The stock has a 50-day moving average price of $37.90 and a two-hundred day moving average price of $39.79. Xenon Pharmaceuticals Inc. has a 12 month low of $33.27 and a 12 month high of $46.00. The company has a market capitalization of $2.66 billion, a PE ratio of -12.33 and a beta of 1.26.

Xenon Pharmaceuticals (NASDAQ:XENE) last issued its quarterly earnings data on Thursday, February 27th. The biopharmaceutical company reported ($0.84) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.89) by $0.05. As a group, analysts predict that Xenon Pharmaceuticals Inc. will post -3.1 earnings per share for the current fiscal year.

Insider Transactions at Xenon Pharmaceuticals

In related news, CEO Ian Mortimer sold 22,468 shares of the firm’s stock in a transaction on Friday, January 24th. The stock was sold at an average price of $40.20, for a total transaction of $903,213.60. Following the completion of the transaction, the chief executive officer now directly owns 31,302 shares of the company’s stock, valued at $1,258,340.40. This trade represents a 41.79 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. 5.52% of the stock is owned by company insiders.

Xenon Pharmaceuticals Company Profile

Xenon Pharmaceuticals Inc, a neuroscience-focused biopharmaceutical company, engages in the development of therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN1101, a novel and potent Kv7 potassium channel opener, which is in Phase 3 clinical trials for the treatment of epilepsy and other neurological disorders.